 |
16 Diseases |  |
4 Trials |
|
4 Trials |  |
584 News |  |
| «1234567 |
- | Krystexxa (pegloticase) / Amgen
Trial initiation date: REduCing Immunogenicity to PegloticasE (RECIPE) Study (clinicaltrials.gov) - Mar 3, 2018
P2, N=32, Not yet recruiting, Sponsor: University of Alabama at Birmingham
Initiation date: Jan 2018 --> Mar 2018
- ||| Krystexxa (pegloticase) / Amgen
Enrollment change: TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (clinicaltrials.gov) - Nov 14, 2017
P2, N=177, Recruiting, Sponsor: Ampel BioSolutions, LLC
Initiation date: Jan 2018 --> Mar 2018 N=87 --> 177
- || Krystexxa (pegloticase) / Amgen
Trial primary completion date: TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (clinicaltrials.gov) - Nov 8, 2017
P2, N=87, Recruiting, Sponsor: Ampel BioSolutions, LLC
N=87 --> 177 Trial primary completion date: Dec 2018 --> Dec 2019
- | Krystexxa (pegloticase) / Amgen
New P2 trial: REduCing Immunogenicity to PegloticasE (RECIPE) Study (clinicaltrials.gov) - Oct 5, 2017
P2, N=32, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- ||| Krystexxa (pegloticase) / Amgen
Enrollment change, Trial primary completion date: TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (clinicaltrials.gov) - Sep 15, 2017
P2, N=87, Recruiting, Sponsor: Ampel BioSolutions, LLC
Trial primary completion date: Dec 2018 --> Dec 2019 N=53 --> 87 | Trial primary completion date: Dec 2017 --> Dec 2018
- ||| Krystexxa (pegloticase) / Amgen
Trial completion: EyesOnGOUT: Observational Study of the Use of Pegloticase (KRYSTEXXA (clinicaltrials.gov) - Jul 19, 2017
P=N/A, N=187, Completed, Sponsor: Horizon Pharma Rheumatology LLC
N=53 --> 87 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- || Krystexxa (pegloticase) / Amgen
Enrollment closed, Enrollment change: EyesOnGOUT: Observational Study of the Use of Pegloticase (KRYSTEXXA (clinicaltrials.gov) - Jun 12, 2017
P=N/A, N=187, Active, not recruiting, Sponsor: Horizon Pharma Rheumatology LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=1500 --> 187
- || Krystexxa (pegloticase) / Amgen
Trial primary completion date: TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (clinicaltrials.gov) - Jan 24, 2017
P2, N=53, Recruiting, Sponsor: Ampel BioSolutions, LLC
Recruiting --> Active, not recruiting | N=1500 --> 187 Trial primary completion date: Dec 2016 --> Dec 2017
- ||| Krystexxa (pegloticase) / Amgen
Enrollment change: TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (clinicaltrials.gov) - Sep 7, 2016
P2, N=53, Recruiting, Sponsor: Ampel BioSolutions, LLC
Trial primary completion date: Dec 2016 --> Dec 2017 N=33 --> 53
- Krystexxa (pegloticase) / Amgen
Trial primary completion date: EyesOnGOUT: Observational Study of the Use of Pegloticase (KRYSTEXXA (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=1500, Recruiting, Sponsor: Horizon Pharma Rheumatology LLC
N=33 --> 53 Trial primary completion date: Jul 2015 --> Jul 2017
- | Krystexxa (pegloticase) / Amgen
Enrollment change: TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (clinicaltrials.gov) - Jun 27, 2016
P2, N=33, Recruiting, Sponsor: Ampel BioSolutions, LLC
Trial primary completion date: Jul 2015 --> Jul 2017 N=20 --> 33
- | Krystexxa (pegloticase) / Amgen
Enrollment open: TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (clinicaltrials.gov) - Dec 21, 2015
P2, N=20, Recruiting, Sponsor: Ampel BioSolutions, LLC
N=20 --> 33 Not yet recruiting --> Recruiting
- Krystexxa (pegloticase) / Amgen
New P2 trial: TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (clinicaltrials.gov) - Nov 8, 2015
P2, N=20, Not yet recruiting, Sponsor: Ampel BioSolutions, LLC
- | Krystexxa (pegloticase) / Amgen, NN1213 / Novo Nordisk
Trial completion: Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout (clinicaltrials.gov) - Oct 2, 2014
P2, N=30, Completed, Sponsor: John Sundy
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Krystexxa (pegloticase) / Amgen
Trial completion: A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: Savient Pharmaceuticals
Recruiting --> Completed No longer recruiting --> Completed
- | Krystexxa (pegloticase) / Amgen
Trial completion: Study to Assess Pegloticase (KRYSTEXXA (clinicaltrials.gov) - Oct 23, 2013
P1, N=12, Completed, Sponsor: Savient Pharmaceuticals
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Krystexxa (pegloticase) / Amgen
New P1 trial: Study to Assess Pegloticase (KRYSTEXXA (clinicaltrials.gov) - Nov 29, 2012
P1, N=12, Completed, Sponsor: Savient Pharmaceuticals